UK Markets open in 7 hrs 19 mins

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
517.93+0.02 (+0.00%)
At close: 4:00PM EST
Currency in USD

Valuation measures

Market cap (intra-day) 555.27B
Enterprise value 354.33B
Trailing P/E 18.98
Forward P/E 113.90
PEG ratio (5-yr expected) 11.42
Price/sales (ttm)5.98
Price/book (mrq)5.39
Enterprise value/revenue 35.88
Enterprise value/EBITDA 616.22

Trading information

Stock price history

Beta (5Y monthly) 0.30
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 3664.64
52-week low 3328.13
50-day moving average 3494.23
200-day moving average 3567.27

Share statistics

Avg vol (3-month) 3907.91k
Avg vol (10-day) 31.06M
Shares outstanding 5104.86M
Float 100.8M
% held by insiders 12.90%
% held by institutions 192.17%
Shares short (30 Dec 2020) 42.25M
Short ratio (30 Dec 2020) 42.38
Short % of float (30 Dec 2020) 42.91%
Short % of shares outstanding (30 Dec 2020) 42.11%
Shares short (prior month 29 Nov 2020) 42.13M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)29 Sep 2020

Profitability

Profit margin 34.14%
Operating margin (ttm)33.76%

Management effectiveness

Return on assets (ttm)12.99%
Return on equity (ttm)30.60%

Income statement

Revenue (ttm)9.24B
Revenue per share (ttm)85.17
Quarterly revenue growth (yoy)31.60%
Gross profit (ttm)4.04B
EBITDA 3.35B
Net income avi to common (ttm)3.16B
Diluted EPS (ttm)27.29
Quarterly earnings growth (yoy)25.80%

Balance sheet

Total cash (mrq)3.03B
Total cash per share (mrq)28.67
Total debt (mrq)2.69B
Total debt/equity (mrq)26.61
Current ratio (mrq)3.89
Book value per share (mrq)96.01

Cash flow statement

Operating cash flow (ttm)2.17B
Levered free cash flow (ttm)733.91M